Pharmacotherapy is a viable option in the treatment of women with endometriosis

&NA;
In: Drugs & Therapy Perspectives · 2009 · vol. 25(12) , pp. 9–13 · doi:10.2165/11204040-000000000-00000 · W4246936836
article OA: closed CC0
Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-08 ⓘ

This article reviews current pharmacological treatments for endometriosis, including oral contraceptives, progestins, GnRH agonists, and aromatase inhibitors, indicating pharmacotherapy is a viable treatment option.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-09 · read from full text ⓘ

This paper is a review discussing pharmacotherapy for women with endometriosis, drawing on prior clinical trials and guidelines across several hormonal and non-hormonal approaches. It highlights evidence supporting multiple drug classes used for endometriosis-associated pain, including progestins and gonadotropin-releasing hormone analogues, and notes newer options such as aromatase inhibitors and progesterone receptor modulators, while citing comparative and placebo-controlled studies and Cochrane reviews. The paper’s main limitation is that it synthesizes published work rather than presenting new primary data, so conclusions depend on the quality and comparability of included studies. This paper is centrally about endometriosis — it reviews pharmacotherapy options used in women for endometriosis-associated pain and related outcomes.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 4,481 characters · extracted from oa-doi-fallback · click to expand
References Ferrero S, Venturini PL, Ragni N, et al. Pharmacological treatment of endometriosis: experience with aromatase inhibitors. Drugs 2009; 69(8): 943–52 Vercellini P, Somigliana E, Viganò P, et al. Endometriosis: current therapies and new pharmacological developments. Drugs 2009; 69(6): 649–75 Crosignani P, Olive D, Bergqvist A, et al. Advances in the management of endometriosis: an update for clinicians. Hum Reprod Update 2006; 12(2): 179–89 Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development Group. Hum Reprod 2005; 20(10): 2698–704 Royal College of Obstetricians and Gynaecologists. The investigation and management of endometriosis: guideline no. 24. London: RCOG Press, 2006 Jun Harada T, Momoeda M, Taketani Y, et al. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril 2008; 90(5): 1583–8 Vercellini P, Frontino G, De Giorgi O, et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhoea that does not respond to a cyclic pill regimen. Fertil Steril 2003; 80(3): 560–3 British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary. No. 57. London: BMJ Publishing Group Ltd and RPS Publishing, 2009 Mar Vercellini P, Somigliana E, Daguati R, et al. Postoperative oral contraceptive exposure and risk of endometrioma recurrence. Am J Obstet Gynecol 2008; 198(5): 504.e1–5 Modugno F, Ness RB, Allen GO, et al. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol 2004; 191: 733–40 Muneyyirci-Delale O, Karacan M. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med 1998; 43(1): 24–7 Moore C, Kohler G, Muller A. The treatment of endometriosis with dienogest. Drugs Today 1999; 35Suppl. C: 41–52 Harrison RF, Barry-Kinsella C. Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study. Fertil Steril 2000; 74(1): 24–30 Bergqvist A, Theorell T. Changes in quality of life after hormonal treatment of endometriosis. Acta Obset Gynecol Scand 2001; 80(7): 628–37 Vercellini P, De Giorgi O, Oldani S, et al. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol 1996; 175(2): 396–401 Crosignani PG, Luciano A, Ray A, et al. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 2006; 21(1): 248–56 Schlaff WD, Carson SA, Luciano A, et al. Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. Fertil Steril 2006; 85(2): 314–25 Olive DL. Optimizing gonadatropin-releasing hormone agonist therapy in women with endometriosis. Treat Endocrinol 2004; 3(2): 83–9 Davis L, Kennedy S, Moore J, et al. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst Rev 2007; (3): CD001019 Prentice A, Deary A, Goldbeck-Wood S, et al. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst Rev 2007; (3): CD000346 Koninckx PR, Craessaerts M, Timmerman D, et al. Anti-TNF-α treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum Reprod 2008; 23(9): 2017–23 Chwalisz K, Mattia-Goldberg C, Lee M, et al. Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) asoprisinil [abstract no. O-207]. Fertil Steril 2004; 82Suppl 2: S83–4 Soysal S, Soysal ME, Ozer S, et al. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod 2004; 19(1): 160–7 Rights and permissions About this article Cite this article Pharmacotherapy is a viable option in the treatment of women with endometriosis. Drugs Ther. Perspect 25, 9–13 (2009). https://doi.org/10.2165/11204040-000000000-00000 Published: Issue date: DOI: https://doi.org/10.2165/11204040-000000000-00000

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (16)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK